UKHSA therapeutic technical briefing published
Latest updates on coronavirus (COVID-19) therapeutic agents, a programme of public health activities to support deployment of novel therapeutics for COVID-19.
The UK Health Security Agency (UKHSA) has started publishing regular technical briefings on the development and effectiveness of therapeutics used to treat patients with COVID-19 in the UK.
Thanks to the success of the vaccination programme, the number of people in hospital or suffering from severe disease has been greatly reduced. There are a number of effective therapeutics in use in the UK to treat those who still encounter serious illness as a result of COVID-19.
The surveillance programme to support the rollout of novel therapeutics will examine the level of access to various treatments, the extent to which emerging mutations and variants may affect efficacy, and the ongoing picture of clinical outcomes.
Updates and early data will be published regularly.
Updates to this page
Last updated 31 January 2022 + show all updates
-
Updated to reflect that the therapeutic technical briefings will no longer be published on a fortnightly basis due to a change in operational requirements. We will continue to provide regular updates and a new technical briefing will be published in due course.
-
First published.